References | Gender | Age | Site of primary tumor | Surgery | Targeted therapy | Treatment line | Other therapya | Treatment response |
---|---|---|---|---|---|---|---|---|
[11] | Male | 69 | Peritoneal cavity | Yes | No | NAb | Yes | NAb |
[12] | Male | 32 | Mesentery | Yes | Apatinib | 2nd | No | PR |
[13] | Male | 31 | Abdominal cavity | Yes | Apatinib | 2nd | Yes | PR |
[14] | Male | 32 | Pleural surface | Yes | Pazopanib | 2nd | No | PR |
[15] | Male | 21 | Pelvis | No | Temsirolimus | 3rd | No | SD |
[18] | Male | 38 | Peritoneal cavity | Yes | Anlotinib | 1st | No | SD |
Our case | Male | 27 | Pelvic and abdominal cavity | No | Anlotinib | 1st and mainteiance | Yes | PR |